Efficacy and safety of a modular multi-modal exercise program in prostate cancer patients with bone metastases: A randomized controlled trial

BMC Cancer

Volumn 11, Issue , 2011, Pages

  Galvão, Daniel A ^a   Taaffe, Dennis R ^b   Cormie, Prue ^a   Spry, Nigel ^c,d   Chambers, Suzanne K ^e,f   Peddle McIntyre, Carolyn ^a   Baker, Michael ^a   Denham, James ^g,h   Joseph, David ^c,d   Groom, Geoff ⁱ   Newton, Robert U ^a  

^a EDITH COWAN UNIVERSITY   (Australia)

^b UNIVERSITY OF NEWCASTLE   (Australia)

^c SIR CHARLES GAIRDNER HOSPITAL   (Australia)

^d UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^e GRIFFITH UNIVERSITY   (Australia)

^f VIERTEL CENTRE FOR RESEARCH IN CANCER CONTROL   (Australia)

^g UNIVERSITY OF NEWCASTLE   (Australia)

^h NEWCASTLE MATER HOSPITAL   (Australia)

ⁱ Perth Radiological Clinic   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; AUSTRALIA; BONE METASTASIS; CANCER PATIENT; CANCER SURVIVOR; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; FOLLOW UP; HUMAN; KINESIOTHERAPY; MAJOR CLINICAL STUDY; MALE; MEDICAL CARE; MULTICENTER STUDY; PATIENT PARTICIPATION; PATIENT SAFETY; PHYSICAL ACTIVITY; PROSPECTIVE STUDY; PROSTATE CANCER; RANDOMIZED CONTROLLED TRIAL; TUMOR LOCALIZATION; ANALYSIS OF VARIANCE; BODY EQUILIBRIUM; BONE TUMOR; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DISABILITY; EXERCISE TEST; FATIGUE; METASTASIS; METHODOLOGY; MUSCLE STRENGTH; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; PROSTATE TUMOR; QUALITY OF LIFE; QUESTIONNAIRE; SKELETAL MUSCLE; WALKING;

ANALYSIS OF VARIANCE; BONE NEOPLASMS; DISABILITY EVALUATION; EXERCISE TEST; EXERCISE THERAPY; FATIGUE; FOLLOW-UP STUDIES; HUMANS; MALE; MUSCLE STRENGTH; MUSCLE, SKELETAL; NEW SOUTH WALES; POSTURAL BALANCE; PROSTATIC NEOPLASMS; QUALITY OF LIFE; QUESTIONNAIRES; WALKING; WESTERN AUSTRALIA;

EID: 83255188957     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-11-517     Document Type: Article

References (47)

1. Small EJ, Smith MR, Seaman JJ, Petrone S, Kowalski MO. Combined analysis of two multicenter, randomized, placebo-controlled studies of pamidronate disodium for the palliation of bone pain in men with metastatic prostate cancer. J Clin Oncol 2003, 21(23):4277-4284. 10.1200/JCO.2003.05.147, 14581438.
2. Fizazi K, Beuzeboc P, Lumbroso J, Haddad V, Massard C, Gross-Goupil M, Di Palma M, Escudier B, Theodore C, Loriot Y, et al. Phase II trial of consolidation docetaxel and samarium-153 in patients with bone metastases from castration-resistant prostate cancer. J Clin Oncol 2009, 27(15):2429-2435. 10.1200/JCO.2008.18.9811, 19364971.
3. Carlin BI, Andriole GL. The natural history, skeletal complications, and management of bone metastases in patients with prostate carcinoma. Cancer 2000, 88(12 Suppl):2989-2994.
4. Saad F, Olsson C, Schulman CC. Skeletal morbidity in men with prostate cancer: quality-of-life considerations throughout the continuum of care. Eur Urol 2004, 46(6):731-739. discussion 739-740, 10.1016/j.eururo.2004.08.016, 15548440.
5. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics. CA Cancer J Clin 2010, 60(5):277-300. 10.3322/caac.20073, 20610543.
6. Lee RJ, Saylor PJ, Smith MR. Treatment and prevention of bone complications from prostate cancer. Bone 2011, 48(1):88-95. 10.1016/j.bone.2010.05.038, 3010497, 20621630.
7. Weinfurt KP, Li Y, Castel LD, Saad F, Timbie JW, Glendenning GA, Schulman KA. The significance of skeletal-related events for the health-related quality of life of patients with metastatic prostate cancer. Ann Oncol 2005, 16(4):579-584. 10.1093/annonc/mdi122, 15734776.
8. Shahinian VB, Kuo YF, Freeman JL, Goodwin JS. Risk of fracture after androgen deprivation for prostate cancer. N Engl J Med 2005, 352(2):154-164. 10.1056/NEJMoa041943, 15647578.
9. Sharifi N, Gulley JL, Dahut WL. Androgen deprivation therapy for prostate cancer. JAMA 2005, 294(2):238-244. 10.1001/jama.294.2.238, 16014598.
10. Diamond TH, Higano CS, Smith MR, Guise TA, Singer FR. Osteoporosis in men with prostate carcinoma receiving androgen-deprivation therapy: recommendations for diagnosis and therapies. Cancer 2004, 100(5):892-899. 10.1002/cncr.20056, 14983482.
11. Galvao DA, Spry NA, Taaffe DR, Newton RU, Stanley J, Shannon T, Rowling C, Prince R. Changes in muscle, fat and bone mass after 36 weeks of maximal androgen blockade for prostate cancer. BJU Int 2008, 102(1):44-47. 10.1111/j.1464-410X.2008.07539.x, 18336606.
12. Galvao DA, Taaffe DR, Spry N, Joseph D, Turner D, Newton RU. Reduced muscle strength and functional performance in men with prostate cancer undergoing androgen suppression: a comprehensive cross-sectional investigation. Prostate Cancer Prostatic Dis 2009, 12(2):198-203. 10.1038/pcan.2008.51, 18852703.
13. Ebeling PR. Clinical practice. Osteoporosis in men. N Engl J Med 2008, 358(14):1474-1482. 10.1056/NEJMcp0707217, 18385499.
14. Oefelein MG, Ricchiuti V, Conrad W, Resnick MI. Skeletal fractures negatively correlate with overall survival in men with prostate cancer. J Urol 2002, 168(3):1005-1007. 10.1016/S0022-5347(05)64561-2, 12187209.
15. Petrylak DP, Tangen CM, Hussain MH, Lara PN, Jones JA, Taplin ME, Burch PA, Berry D, Moinpour C, Kohli M, et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 2004, 351(15):1513-1520. 10.1056/NEJMoa041318, 15470214.
16. Oudard S, Banu E, Beuzeboc P, Voog E, Dourthe LM, Hardy-Bessard AC, Linassier C, Scotte F, Banu A, Coscas Y, et al. Multicenter randomized phase II study of two schedules of docetaxel, estramustine, and prednisone versus mitoxantrone plus prednisone in patients with metastatic hormone-refractory prostate cancer. J Clin Oncol 2005, 23(15):3343-3351. 10.1200/JCO.2005.12.187, 15738542.
17. Coleman RE. Metastatic bone disease: clinical features, pathophysiology and treatment strategies. Cancer Treat Rev 2001, 27(3):165-176. 10.1053/ctrv.2000.0210, 11417967.
18. Eton DT, Lepore SJ. Prostate cancer and health-related quality of life: a review of the literature. Psychooncology 2002, 11(4):307-326. 10.1002/pon.572, 2593110, 12203744.
19. Albertsen PC, Aaronson NK, Muller MJ, Keller SD, Ware JE. Health-related quality of life among patients with metastatic prostate cancer. Urology 1997, 49(2):207-216. discussion 216-207, 10.1016/S0090-4295(96)00485-2, 9037282.
20. Windsor PM, Nicol KF, Potter J. A randomized, controlled trial of aerobic exercise for treatment-related fatigue in men receiving radical external beam radiotherapy for localized prostate carcinoma. Cancer 2004, 101(3):550-557. 10.1002/cncr.20378, 15274068.
21. Galvao DA, Nosaka K, Taaffe DR, Peake J, Spry N, Suzuki K, Yamaya K, McGuigan MR, Kristjanson LJ, Newton RU. Endocrine and immune responses to resistance training in prostate cancer patients. Prostate Cancer Prostatic Dis 2008, 11(2):160-165. 10.1038/sj.pcan.4500991, 17637762.
22. Galvao DA, Taaffe DR, Spry N, Joseph D, Newton RU. Combined resistance and aerobic exercise program reverses muscle loss in men undergoing androgen suppression therapy for prostate cancer without bone metastases: a randomized controlled trial. J Clin Oncol 2010, 28(2):340-347. 10.1200/JCO.2009.23.2488, 19949016.
23. Galvao DA, Nosaka K, Taaffe DR, Spry N, Kristjanson LJ, McGuigan MR, Suzuki K, Yamaya K, Newton RU. Resistance training and reduction of treatment side effects in prostate cancer patients. Med Sci Sports Exerc 2006, 38(12):2045-2052. 10.1249/01.mss.0000233803.48691.8b, 17146309.
24. Segal RJ, Reid RD, Courneya KS, Sigal RJ, Kenny GP, Prud'Homme DG, Malone SC, Wells GA, Scott CG, Slovinec D'Angelo ME. Randomized controlled trial of resistance or aerobic exercise in men receiving radiation therapy for prostate cancer. J Clin Oncol 2009, 27(3):344-351.
25. Segal RJ, Reid RD, Courneya KS, Malone SC, Parliament MB, Scott CG, Venner PM, Quinney HA, Jones LW, D'Angelo ME, et al. Resistance exercise in men receiving androgen deprivation therapy for prostate cancer. J Clin Oncol 2003, 21(9):1653-1659. 10.1200/JCO.2003.09.534, 12721238.
26. Schmitz KH, Courneya KS, Matthews C, Demark-Wahnefried W, Galvao DA, Pinto BM, Irwin ML, Wolin KY, Segal RJ, Lucia A, et al. American College of Sports Medicine roundtable on exercise guidelines for cancer survivors. Med Sci Sports Exerc 2010, 42(7):1409-1426. 10.1249/MSS.0b013e3181e0c112, 20559064.
27. Galvao DA, Taaffe DR. Resistance exercise dosage in older adults: single- versus multiset effects on physical performance and body composition. J Am Geriatr Soc 2005, 53(12):2090-2097. 10.1111/j.1532-5415.2005.00494.x, 16398892.
28. Taaffe DR, Duret C, Wheeler S, Marcus R. Once-weekly resistance exercise improves muscle strength and neuromuscular performance in older adults. J Am Geriatr Soc 1999, 47(10):1208-1214.
29. Myers AM, Fletcher PC, Myers AH, Sherk W. Discriminative and evaluative properties of the activities-specific balance confidence (ABC) scale. J Gerontol A Biol Sci Med Sci 1998, 53(4):M287-294.
30. Taaffe DR, Henwood TR, Nalls MA, Walker DG, Lang TF, Harris TB. Alterations in muscle attenuation following detraining and retraining in resistance-trained older adults. Gerontology 2009, 55(2):217-223. 10.1159/000182084, 2756799, 19060453.
31. Ware JE, Gandek B. Overview of the SF-36 health survey and the international quality of life assessment (IQOLA) project. J Clin Epidemiol 1998, 51(11):903-912. 10.1016/S0895-4356(98)00081-X, 9817107.
32. Broom R, Du H, Clemons M, Eton D, Dranitsaris G, Simmons C, Ooi W, Cella D. Switching breast cancer patients with progressive bone metastases to third-generation bisphosphonates: measuring impact using the functional assessment of cancer therapy-bone pain. J Pain Symptom Manage 2009, 38(2):244-257. 10.1016/j.jpainsymman.2008.08.005, 19364633.
33. Sayers SP, Jette AM, Haley SM, Heeren TC, Guralnik JM, Fielding RA. Validation of the late-life function and disability instrument. J Am Geriatr Soc 2004, 52(9):1554-1559. 10.1111/j.1532-5415.2004.52422.x, 15341561.
34. Chambers SK, Lynch BM, Aitken J, Baade P. Relationship over time between psychological distress and physical activity in colorectal cancer survivors. J Clin Oncol 2009, 27(10):1600-1606. 10.1200/JCO.2008.18.5157, 19255326.
35. Roth AJ, Rosenfeld B, Kornblith AB, Gibson C, Scher HI, Curley-Smart T, Holland JC, Breitbart W. The memorial anxiety scale for prostate cancer: validation of a new scale to measure anxiety in men with with prostate cancer. Cancer 2003, 97(11):2910-2918. 10.1002/cncr.11386, 12767107.
36. Sundin EC, Horowitz MJ. Impact of event scale: psychometric properties. Br J Psychiatry 2002, 180:205-209. 10.1192/bjp.180.3.205, 11872511.
37. Reddy S, Bruera E, Pace E, Zhang K, Reyes-Gibby CC. Clinically important improvement in the intensity of fatigue in patients with advanced cancer. J Palliat Med 2007, 10(5):1068-1075. 10.1089/jpm.2007.0007, 17985963.
38. Cramp F, Daniel J. Exercise for the management of cancer-related fatigue in adults. Cochrane Database Syst Rev 2008, 16(2):CD006145.
39. Beck SL, Schwartz AL, Towsley G, Dudley W, Barsevick A. Psychometric evaluation of the Pittsburgh sleep quality index in cancer patients. J Pain Symptom Manage 2004, 27(2):140-148. 10.1016/j.jpainsymman.2003.12.002, 15157038.
40. Buysse DJ, Reynolds CF, Monk TH, Berman SR, Kupfer DJ. The Pittsburgh sleep quality index: a new instrument for psychiatric practice and research. Psychiatry Res 1989, 28(2):193-213. 10.1016/0165-1781(89)90047-4, 2748771.
41. Ajzen I. The theory of planned behavior. Orgn Behav Hum Dec Processes 1991, 50:179-211.
42. Plasqui G, Westerterp KR. Physical activity assessment with accelerometers: an evaluation against doubly labeled water. Obesity (Silver Spring) 2007, 15(10):2371-2379.
43. Galvao DA, Spry N, Taaffe DR, Denham J, Joseph D, Lamb DS, Levin G, Duchesne G, Newton RU. A randomized controlled trial of an exercise intervention targeting cardiovascular and metabolic risk factors for prostate cancer patients from the RADAR trial. BMC Cancer 2009, 9(1):419. 10.1186/1471-2407-9-419, 2790468, 19951446.
44. Newton RU, Taaffe DR, Spry N, Gardiner RA, Levin G, Wall B, Joseph D, Chambers SK, Galvao DA. A phase III clinical trial of exercise modalities on treatment side-effects in men receiving therapy for prostate cancer. BMC Cancer 2009, 9:210. 10.1186/1471-2407-9-210, 2713263, 19563641.
45. Galvao DA, Taaffe DR, Spry N, Joseph D, Newton RU. Acute versus chronic exposure to androgen suppression for prostate cancer: impact on the exercise response. J Urol 2011, 186(4):1291-1297. 10.1016/j.juro.2011.05.055, 21849187.
46. Newton RU, Hakkinen K, Hakkinen A, McCormick M, Volek J, Kraemer WJ. Mixed-methods resistance training increases power and strength of young and older men. Med Sci Sports Exerc 2002, 34(8):1367-1375. 10.1097/00005768-200208000-00020, 12165694.
47. Galvao DA, Newton RU. Review of exercise intervention studies in cancer patients. J Clin Oncol 2005, 23(4):899-909. 10.1200/JCO.2005.06.085, 15681536.